I personally don’t remember anything regarding t

I personally don’t remember anything regarding the mentioning of the data being unusable, but if it was, then why would CYDY bother with resubmitting the other 2 parts and setting expectations for the clinical part submission on Q2? And why would they sue Amarex to access the data and go through all that effort and $$$, and if it is unusable, May be then we can sue Amarex again for generating worthless data, and get some sort of reimbursement, then that will rise the share price a little bit? Either way, it is still a win win win.